iRhythm Authorizes Share Repurchases of Up to $200 Million
Key Facts
iRhythm approved a program to repurchase up to $200 million of its common stock, in a decision approved by the board on November 10 and announced by the company on November 11, according to its filing with the U.S. Securities and Exchange Commission. The authorization sets a ceiling on potential purchases, but does not mean the company has bought shares for that amount or will exhaust the program. iRhythm said the approval reflects confidence in the continued strength of its core business, along with new growth opportunities associated with the addition of VitalConnect’s operations. The announcement comes as the company reported quarterly revenue growth alongside a wider net loss compared with the same period a year earlier. JPM stock closed at $330.6 on November 17, according to EL7 data, but that movement does not prove that a repurchase agreement with the bank was executed.
The program allows shares to be repurchased through open-market transactions, privately negotiated transactions or accelerated share repurchase agreements, according to iRhythm’s filing with the SEC. The company said the amount and timing of purchases would be determined at its discretion, based on market conditions and the company’s needs. The authorization therefore provides more than one way to carry out purchases, but does not set in advance the value or timing of any transaction. iRhythm also confirmed that the program does not obligate it to purchase a specific amount or number of shares. The board may amend, suspend or terminate the program, according to the same filing.
iRhythm expects to fund any purchases with available cash and cash equivalents and ongoing cash flows from operations. That statement does not establish that any specific amount has been allocated or spent on repurchases; it describes the funding sources the company expects to rely on. On October 5, iRhythm completed its acquisition of VitalConnect for approximately $237.5 million in cash, with the possibility of issuing additional shares under the closing terms, according to its quarterly report filed with the SEC. The company linked the program’s approval to growth opportunities it said had emerged from adding VitalConnect’s operations. The deal provides context for the capital allocation decision, while the filing did not specify the expected financial impact of the new growth opportunities.
iRhythm’s revenue in the third quarter of 2026 was about $221.6 million, up 14.9% from $192.9 million in the third quarter of 2025, according to its earnings release filed with the SEC. The company attributed the increase mainly to continued volume demand across its customer base and new growth channels. By contrast, it recorded a net loss of $29.851 million in the third quarter of 2026, compared with a loss of $5.212 million in the same period of 2025, according to the financial statements table in its quarterly report. The results show two concurrent performance trends: revenue growth and a wider year-over-year net loss. The company said the strength of its core business and growth opportunities associated with VitalConnect were among the reasons for approving the authorization, but the filing did not say that repurchases would change operating results or the loss.
The revolving credit agreement with JPMorgan provides financial context separate from the repurchase program. iRhythm said in its quarterly report that it entered into a secured revolving credit agreement with a maximum commitment of $300 million on November 3, and that no amounts were drawn under it at closing. The company said the credit agreement restricts share repurchases, subject to exceptions and conditions related to leverage ratios and defaults. Even when leverage ratio tests are not met, the agreement permits repurchases of common stock totaling up to $30 million per fiscal year. This limit in the credit agreement remains distinct from the announced program’s $200 million ceiling, as each pertains to a different contractual framework.